Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 8/20 | 0.34 |
| ▸ | GIPR | P48546 | 6/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | DVL1 | O14640 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959762 | 0.88 | RAB9A (0.39) | RAB9ANPC1KMT2AMEN1POLB | |
| SCHEMBL4954893 | 0.85 | RAB9A (0.40) | RAB9ANPC1KMT2AMEN1POLB | |
| SCHEMBL4956438 | 0.83 | PTPN1 (0.48) | RAB9ANPC1KMT2AMEN1POLB | |
| SCHEMBL4957254 | 0.76 | KDM4E (0.38) | RAB9ANPC1KMT2AMEN1POLB | |
| SCHEMBL4955541 | 0.76 | PTPRB (0.45) | RAB9ANPC1PTPN1PTPN2KDM4E | |
| SCHEMBL4956610 | 0.75 | PTPRB (0.47) | RAB9AKMT2AMEN1GCGRGIPR | |
| SCHEMBL4954863 | 0.75 | PTPN1 (0.46) | RAB9AKMT2AMEN1PTPN1PTPN2 | |
| SCHEMBL4959046 | 0.74 | GCGR (0.43) | GCGRGIPR | |
| SCHEMBL4959280 | 0.74 | GCGR (0.47) | GCGRGIPR | |
| SCHEMBL4955550 | 0.74 | PTPN1 (0.45) | RAB9ANPC1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | IMPINJ, INC. | 2008-08-21 | — | — | US | claimed |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | PTPN1, PTPN5, PTPN18 | RAB9A 2890/4885NPC1 4858/4885KMT2A 1604/4885 |
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | PTPN1, PTPN5, PTPN18 | RAB9A 2890/4885NPC1 4858/4885KMT2A 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.